sEH/AChE-IN-5
sEH/AChE-IN-5 is a selective, orally active and brain-penetrant acetylcholinesterase (AChE) and soluble epoxide hydrolase (sEH) dual inhibitor with IC50 values of 1.7 nM and 0.7 nM. sEH/AChE-IN-5 mediates neuroprotection and anti-inflammation via reduced TNF-α, IL-1β, IL-6, iNOS. sEH/AChE-IN-5 improves Scopolamine (HY-N0296)-induced learning and memory deficits mice. sEH/AChE-IN-5 can be used for the research of Alzheimer's disease.
For research use only. We do not sell to patients.
- Formula: C34H29ClF3N7O2
- Molecular Weight:660.09
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
AChE 1.7 nM (IC50) |
sEH 0.7 nM (IC50) |
IL-1β |
IL-6 |
In Vitro
sEH/AChE-IN-5 (Compound z43) potently inhibits recombinant hAChE with an IC50 of 1.7 nM and inhibits hBuChE with an IC50 of 942.0 nM[1].
sEH/AChE-IN-5 potently inhibits recombinant hsEH with an IC50 of 0.7 nM[1].
sEH/AChE-IN-5 (20 μM; 48 h) exhibits low cytotoxicity in HepG2, SMMC7721, and SH-SY5Y cell lines, with IC50 values of 82.27 μM, >100 μM, and >20 μM respectively[1].
sEH/AChE-IN-5 (1.25-20 μM) exhibits no significant cytotoxicity in PC12 and BV-2 cell lines at concentrations up to 20 μM[1].
sEH/AChE-IN-5 (5-20 μM; 26 h) protects PC12 cells from H2O2-induced toxicity, increasing cell viability by over 20% at 5 μM in a dose-dependent manner[1].
sEH/AChE-IN-5 (5-20 μM; 1 h pretreatment) dose-dependently reduces LPS (HY-D1056)-induced TNF-α, IL-1β, IL-6, and iNOS levels in BV-2 cells, restoring inflammatory factor levels to near normal at 20 μM[1].
sEH/AChE-IN-5 does not inhibit CYP1A2, shows moderate inhibition of CYP2C9, CYP2C19, and CYP2D6, strongly inhibits CYP3A4 (IC50 = 0.324 μM), and exhibits high BBB permeability via PAMPA (Pe = 3.33 × 10-6 cm/s)[1].
sEH/AChE-IN-5 shows high plasma protein binding in human, dog plasma, with over 99.9% bound in all tested species[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BV-2 cells
-
Concentration:5, 10, 20 μM
-
Incubation Time:1 h pretreatment before LPS
-
Result:Does-dependently reduces LPS-induced TNF-α, IL-1β, IL-6.
Restored inflammatory factor levels to near normal at 20 μM.
In Vivo
sEH/AChE-IN-5 (30-1200 mg/kg; i.g.) exhibits favorable acute safety in female Kunming mice, with no observed organ toxicity or adverse events[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Alzheimer's disease ICR mice (male, 3-4 weeks old, 18-22 g, Scopolamine-induced cognitive impairment)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 30 mg/kg
-
Administration:I.g.; daily; 11 days
-
Result:Increased Scopolamine-reduced spontaneous alternation rate from 42.28% to 55.93% (5 mg/kg), 56.79% (10 mg/kg), and 59.35% (30 mg/kg) in the Y-maze test.
Maintained stable total arm entries across all groups, indicating no motor impairment.
Increased Scopolamine-reduced discrimination index from 11.80% to 21.62% (5 mg/kg), 23.82% (10 mg/kg), and 27.99% (30 mg/kg) in the novel object recognition test.
Reversed Scopolamine-elevated brain acetylcholinesterase activity in a dose-dependent manner.
Chemical Information
-
Molecular Weight 660.09
-
Formula C34H29ClF3N7O2
-
SMILES
O=C(NCC1=CC=C(C#N)C=C1C(F)(F)F)C2=CC=CC(OCC3=CN(CCNC4=C(CCCC5)C5=NC6=CC(Cl)=CC=C64)N=N3)=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Protocol for Shuttle Box Test (TDPA)
The Shuttle Box Test for TDPA, or temporally dissociated passive avoidance, measures hippocampus-dependent associative learning by testing whether a rodent avoids entering a dark compartment that was previously paired with foot shock after a temporal delay between dark-compartment entry and shock delivery. The main behavioral readout is crossover or step-through latency from the light chamber into the dark chamber; increased latency across training or retention trials reflects learned avoidance memory rather than motor performance alone.
-
Protocol for Water Maze
The Morris Water Maze is a rodent spatial learning and memory assay in which a mouse or rat swims in opaque water to find an escape platform; in the hidden-platform version, the animal cannot see the platform and must use distal extra-maze cues to learn its fixed spatial location. The assay primarily measures hippocampus-dependent spatial learning during acquisition trials and spatial reference memory during probe trials after platform removal; readouts include escape latency, swim path length, swim speed, quadrant occupancy, platform-site crossings, and proximity to the former platform location.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)